T he USFDA has granted accelerated approval to adagrasib for treating adult patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). Adagrasib is a RAS GTPase family inhibitor that can be used for patients who have received at least one systemic therapy. The approval was given based on the findings of a multicenter, single-arm, open-label clinical trial that included 112 patients with locally advanced or metastatic NSCLC with KRAS G12C mutation.
Study overview ## Adverse reactions (≥ 20%) ## Diarrhea Nausea Fatigue Vomiting Musculoskeletal pain Hepatotoxicity Renal impairment Dyspnea Edema Decreased appetite Cough Pneumonia Dizziness Constipation Abdominal pain## The USFDA has also approved a real-time PCR kit to be used as companion diagnostics for adagrasib. In case there is no mutation detected in the plasma specimen, the tumor tissue needs to be tested. The recommended…
